{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:36:42Z","timestamp":1790239002421,"version":"4.1.0"},"reference-count":137,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["Systems biology of Clostridium difficile infection"],"award-info":[{"award-number":["Systems biology of Clostridium difficile infection"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM007863"],"award-info":[{"award-number":["T32GM007863"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["nyaspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Clostridium difficile<\/jats:italic> is the leading infectious cause of antibiotic\u2010associated diarrhea and colitis. <jats:italic>C. difficile<\/jats:italic> infection (CDI) places a heavy burden on the healthcare system, with nearly half a million infections yearly and an approximate 20% recurrence risk after successful initial therapy. The high incidence has driven new research on improved prevention such as the emerging use of probiotics, intestinal microbiome manipulation during antibiotic therapies, vaccinations, and newer antibiotics that reduce the disruption of the intestinal microbiome. While the treatment of acute <jats:italic>C. difficile<\/jats:italic> is effective in most patients, it can be further optimized by adjuvant therapies that improve the initial treatment success and decrease the risk of subsequent recurrence. Finally, the high risk of recurrence has led to multiple emerging therapies that target toxin activity, recovery of the intestinal microbial community, and elimination of latent <jats:italic>C. difficile<\/jats:italic> in the intestine. In summary, CDIs illustrate the complex interaction among host physiology, microbial community, and pathogen that requires specific therapies to address each of the factors leading to primary infection and recurrence.<\/jats:p>","DOI":"10.1111\/nyas.13958","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T01:26:06Z","timestamp":1537579566000},"page":"110-138","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Novel therapies and preventative strategies for primary and recurrent <i>Clostridium difficile<\/i> infections"],"prefix":"10.1111","volume":"1435","author":[{"given":"Michael G.","family":"Dieterle","sequence":"first","affiliation":[{"name":"Medical Scientist Training Program (MSTP) University of Michigan Medical School  Ann Arbor Michigan"},{"name":"Department of Microbiology and Immunology University of Michigan  Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Rao","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Department of Internal Medicine University of Michigan  Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent B.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology University of Michigan  Ann Arbor Michigan"},{"name":"Infectious Diseases Division, Department of Internal Medicine University of Michigan  Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408913"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.9763"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/521865"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-81-4-429"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1935.01970020105010"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/6.Supplement_1.S235"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051590"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051639"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1085"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2014.04.003"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01765-07"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01260-08"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2015.1127483"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2017.03.004"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00045-15"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fux048"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8050134"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins7124874"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2014.88"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt477"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.17103"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ254"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098400"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/651706"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/596315"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-012-1556-6"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.220"},{"key":"e_1_2_8_29_1","unstructured":"Optimer Pharmaceuticals Inc. Drug insert: NDA 201 699. In:Administration USFaD Ed."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-016-0122-1"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70374-7"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit346"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu069"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30751-X"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01623-06"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2009.08.004"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr377"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12111"},{"key":"e_1_2_8_40_1","unstructured":"Salix Pharmaceuticals Inc. Drug insert: reference ID 3469913. In:Administration USFaD Ed."},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu313"},{"key":"e_1_2_8_42_1","unstructured":"US National Library of Medicine.2018.clinicaltrials.gov. Accessed January 15 2018.https:\/\/clinicaltrials.gov\/ct2\/results?cond=Clostridium+difficile."},{"key":"e_1_2_8_43_1","unstructured":"HCUP National Inpatient Sample (NIS).Healthcare cost and utilization project (HCUP).1993\u20132014. Accessed January 15 2018.www.hcup-us.ahrq.gov\/nisoverview.jsp."},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581815623236"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2016.05.015"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0420-0"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02197-16"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.66"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000410"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ178"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.11"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2013.02.019"},{"key":"e_1_2_8_53_1","unstructured":"DuPont.2012.New study results\u2014HOWARU\u00ae restore formulation. Accessed January 15 2018.http:\/\/www.danisco.com\/about-dupont\/news\/news-archive\/2012\/new-study-results-howarur-restore-formulation\/."},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.11.053"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.47713-0"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03592-3"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.098"},{"key":"e_1_2_8_58_1","unstructured":"Dubischar K.et\u00a0al.2016.A phase 2 dose\u2010confirmation immunogenicity and safety study of Vla84 aClostridium difficilevaccine candidate in adults aged 50 years and older (abstract). InASM Microbe 2016. Boston Massachusetts."},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.065"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.028"},{"key":"e_1_2_8_61_1","unstructured":"Sanofi. Sanofi ends development ofClostridium difficilevaccine [press release]."},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.04.017"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.066712-0"},{"key":"e_1_2_8_64_1","unstructured":"CDVAX.2018. Progress Accessed January 15 2018.http:\/\/cdvax.org\/progress\/."},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-1905-x"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000000990"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv452"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01831-13"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt401"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.07.015"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00504-15"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2017.10.008"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02760-16"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp037"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp042"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06354-11"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04252-14"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04251-14"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.03.016"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2014.07.001"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02077-16"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.05.025"},{"key":"e_1_2_8_83_1","unstructured":"FDA.2016.FDA grants QIDP and fast track designations to MCB3837 Morphochem's novel intravenous antibacterial to treatC. difficileinfections [press release]."},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01159-06"},{"key":"e_1_2_8_85_1","unstructured":"Romark L.C.Product information: Alinia (R) nitazoxanide tablets and oral suspension."},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1086\/596552"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1086\/506351"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer.14.36"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E397"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04853-14"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv498"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0759-5"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30235-9"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01087-15"},{"key":"e_1_2_8_95_1","unstructured":"Chesnel L. S.Sambol&D.Gerding.2012.Treatment of CDAD with oral CB\u2010183 315: time to recurrence relapse and reinfection rates compared with vancomycin.Clin. Microbiol. Infect.18: 380."},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw246"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw275"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx299"},{"key":"e_1_2_8_99_1","unstructured":"Wyeth Pharmaceuticals Inc.2013.Drug insert: reference ID 3379756. In:Administration USFaD Ed."},{"key":"e_1_2_8_100_1","unstructured":"Wyeth Pharmaceuticals Inc.2016.Product information: TYGACIL(R) intravenous injection tigecycline intravenous injection."},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70177-3"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1086\/599224"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13742"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05050-14"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1086\/506349"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.8.2340-2347.2001"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit041"},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/152052"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-13"},{"key":"e_1_2_8_110_1","unstructured":"Immuron.2017.Immuron approved to commence clinical study inC. difficileinfection (CDI) [press release]."},{"key":"e_1_2_8_111_1","unstructured":"Braintree Laboratories Inc.2013.NuLytely 181 Web Label. Accessed January 10 2018.http:\/\/www.nulytely.com\/Collateral\/Documents\/GoNuLytely\/NuLYTELY_181.pdf."},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2014.08.017"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-306"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602615"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix809"},{"key":"e_1_2_8_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.03.039"},{"key":"e_1_2_8_117_1","unstructured":"Merck Sharp & Dohme Corp.2016.Product information: ZINPLAVA(TM) IV injection bezlotoxumab IV injection."},{"key":"e_1_2_8_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/evj.12007"},{"key":"e_1_2_8_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03982-5"},{"key":"e_1_2_8_120_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.45773-0"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1086\/525047"},{"key":"e_1_2_8_122_1","unstructured":"Seres Therapeutics Inc.Clostridium difficileinfection (CDI). Accessed January 15 2018.http:\/\/www.serestherapeutics.com\/pipeline\/ser-109."},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv766"},{"key":"e_1_2_8_124_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000320"},{"key":"e_1_2_8_125_1","doi-asserted-by":"publisher","DOI":"10.1177\/0960327115607372"},{"key":"e_1_2_8_126_1","unstructured":"Osel.Clinical pipeline. Accessed January 15 2018.http:\/\/oselinc.com\/home\/clinical-pipeline\/."},{"key":"e_1_2_8_127_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ938"},{"key":"e_1_2_8_128_1","unstructured":"Rebiotix.2017.Rebiotix reports positive top line data from open\u2010label phase 2 trial of RBX2660 in recurrentClostridium difficile[press release]."},{"key":"e_1_2_8_129_1","doi-asserted-by":"crossref","unstructured":"Dubberke Er L.et\u00a0al.2016.Efficacy and safety of RBX2660 for the prevention of recurrentClostridium difficileinfection: results of the PUNCH CD 2 trial(abstract). InID Week 2016. IDSA. New Orleans LA.","DOI":"10.1093\/ofid\/ofw172.1044"},{"key":"e_1_2_8_130_1","unstructured":"Rebiotix I.RBX7455 oralClostridium difficileprevention. Accessed January 15 2018.http:\/\/www.rebiotix.com\/clinical-trials\/rbx7455-oral-c-diff-prevention\/."},{"key":"e_1_2_8_131_1","unstructured":"Rebiotix.2017.Rebiotix announces expansion of phase 1 trial of the company's oral capsule microbiota product RBX7455 following successful completion of initial study arms [press release]."},{"key":"e_1_2_8_132_1","unstructured":"Healio.2018.FDA fast\u2010tracks Finch's microbiome capsule forC. difficile. Accessed January 15 2018.https:\/\/www.healio.com\/gastroenterology\/infection\/news\/online\/%7Bba5c32ca-10fc-4592-aee9-dc669b59d57b%7D\/fda-fast-tracks-finchs-microbiome-capsule-for-c-difficile."},{"key":"e_1_2_8_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.6"},{"key":"e_1_2_8_134_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00913-12"},{"key":"e_1_2_8_135_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3725"},{"key":"e_1_2_8_136_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix947"},{"key":"e_1_2_8_137_1","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2018.16"},{"key":"e_1_2_8_138_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis833"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnyas.13958","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.13958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T04:47:11Z","timestamp":1694494031000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/nyas.13958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":137,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1111\/nyas.13958"],"URL":"https:\/\/doi.org\/10.1111\/nyas.13958","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]},"assertion":[{"value":"2018-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}